These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments. Evans M; Roberts A; Davies S; Rees A Drugs; 2004; 64(11):1181-96. PubMed ID: 15161326 [TBL] [Abstract][Full Text] [Related]
12. HDL-Targeting Therapeutics: Past, Present and Future. Zakiev E; Feng M; Sukhorukov V; Kontush A Curr Pharm Des; 2017; 23(8):1207-1215. PubMed ID: 27799042 [TBL] [Abstract][Full Text] [Related]
13. HDL-C: role as a risk modifier. Barter P Atheroscler Suppl; 2011 Nov; 12(3):267-70. PubMed ID: 22152280 [TBL] [Abstract][Full Text] [Related]
14. Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: the OCEANS study. Karas RH; Kashyap ML; Knopp RH; Keller LH; Bajorunas DR; Davidson MH Am J Cardiovasc Drugs; 2008; 8(2):69-81. PubMed ID: 18422390 [TBL] [Abstract][Full Text] [Related]
16. Role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors ("statins") in familial combined hyperlipidemia. Schonfeld G; Aguilar-Salina C; Elias N Am J Cardiol; 1998 Feb; 81(4A):43B-46B. PubMed ID: 9526813 [TBL] [Abstract][Full Text] [Related]